- POAI
plans to have first predictive model of ovarian cancer ready for initial
commercialization in Q1 2020
- First
batch of 400 ovarian cancer subjects in initiative has been sequenced
- Groundbreaking
AI-driven model of ovarian cancer will be capable of predicting tumor drug
response, patient outcome
Predictive Oncology Inc. (NASDAQ: POAI), a company focused
on applying artificial intelligence to personalized medicine and drug
discovery, has updated the commercialization of its pioneering CancerQuest 2020
initiative (http://ibn.fm/gs5Qh).
Based on the updated announcement, the company plans on having its first
predictive model of ovarian cancer ready for initial commercialization in
revenue-generating projects with Pharma in Q1 2020.
POAI’s CancerQuest 2020 initiative has been driven Helomics,
a Predictive Oncology subsidiary which has worked closely with collaborators at
the University of Pittsburgh Medical Center (UPMC)-Magee Women’s
Hospital to optimize and scale the genomic and transcriptomic data that has
been gathered. The first batch of the 400 ovarian cancer subjects has been
sequenced, and Helomics is confident that the remaining subjects will move
forward on schedule.
The sequencing marks the completion of one of five
milestones outlined by POAI in its groundbreaking initiative designed to look
at both tumor mutations (genome) as well as tumor gene expression
(transcriptome) to build a comprehensive multi-omic picture of ovarian
tumor (http://ibn.fm/noUgA).
“We are also using deep learning on histopathology images of
the tumor tissue (tissue-omics) to add an additional dimension to this
multi-omic profile,” explained Helomics CTO Dr. Mark Collins. “We believe
the combination of the rich multi-omic profile of the tumor and clinical
outcome data will allow us to build an AI-driven model of ovarian cancer
capable of predicting the tumor drug response and patient outcome (prognosis).”
POAI anticipates receiving the outcome data on the 400
subjects in this retrospective trial from its collaborators at Magee Women’s
Hospital shortly. Helomics intends to use the multi-omic data along with
existing drug-response profiles and the outcome data to build its first
AI-driven predictive model of ovarian cancer; the company expects the model to
be commercialized in Q1 2020.
“We believe that this effort will enhance our understanding
of the molecular profiles of women with ovarian cancer by using the power of
artificial intelligence to create predictive models of therapeutic success,”
said Dr. Robert Edwards, professor and chair of the Department of Obstetrics,
Gynecology and Reproductive Sciences in the University of Pittsburgh School of
Medicine (http://ibn.fm/I7qrx). “We
are excited about the potential for AI-powered, evidence-based decision making
to increase our ability to bring about successful outcomes.”
In addition, Helomics intends to sequence 50% of its
38,000-plus ovarian tumors in the upcoming year, creating what may be the
world’s first comprehensive, actionable multi-omic data set for ovarian cancer.
And Helomics doesn’t plan on stopping there. The company is already evaluating
ways to sequence other cancers types in its database to build additional
AI-driven predictive models, strengthening the company’s presence in both the
clinical and research markets.
Predictive Oncology, which began as a joint venture between
Skyline Medical and Helomics, is ideally positioned to harness the power of
artificial intelligence and work with the pharmaceutical, diagnostic and
biotech industries to develop highly customizable assessment methods for cancer
patients.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
